Infection

Investigators found that the gender life expectancy gap increased 0.23 years from 2010 to 2019 and 0.70 years from 2019 to 2021.

According to the US CDC, the most important modifiable risk factor for antibiotic resistance is (fill in this blank). Find out here and fill in 5 more blanks.

Your daily dose of the clinical news you may have missed.

Get a quick look at the 5 states ranking highest and lowest on metrics including flu vaccination, tetanus vaccination, HPV vaccination, and more.

In this at-a-glance Guideline Topline, we summarize the CDC's 2023 guidance on outpatient antimicrobial stewardship for busy primary care clinicians.

Remdesivir use was associated with increased survival among patients hospitalized with COVID-19 requiring supplemental oxygen across SARS-CoV-2 variants of concern, report researchers.

Get a topline look at 8 of the many studies premiered at IDWeek that have outcomes of interest to primary care clinicians.

The flexibility to self administer a flu vaccine or to administer to another in a non-clinical setting could greatly expand both access and vaccine uptake.

The Pfizer product is the first vaccine indicated to prevent the 5 most common serogroups causing meningococcal disease in adolescents and young adults.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

IDWeek 2023: Infectious disease specialist, Gopi Patel, MD, discusses universal masking in health care settings.

Gopi Patel, MD, emphasizes the importance of promoting vaccination and infection prevention measures among fellow clinicians, as well as patients, this season.

Your daily dose of the clinical news you may have missed.

IDWeek 2023 chair Yun points to climate change and other human-driven devastation of the biosphere as the global threats that will cause disease at local levels.

IDWeek 2023. New study found just slightly more than half of prescriptions for cabotegravir for HIV PrEP resulted in at least 1 injection, suggesting limitations in use and access to the injectable HIV integrase inhibitor.

IDWeek 2023: Older adults hospitalized with respiratory syncytial virus were more likely to be women, be immunocompromised, and to have traveled within the prior 2 weeks,

IDWeek 2023. Results highlight potential impact of influenza vaccination in reducing CV, respiratory, and other complications in adults aged ≥65 years with underlying chronic conditions.

The phase 2 study found that nAB responses against epithelial cell infection were strong after each mRNA-1647 dose and sustained through 12 months.

A phase 3 study found VE from a single shot against RSV-LRTD in adults aged ≥60 years persisted through a second season; revaccination did not increase protection.

IDWeek 2023. The study identified disparities in coverage related to age, race, ethnicity, household income, insurance status, and prior influenza vaccination.

IDWeek 2023. New data shows non-Hispanic Black patients had a 13% lower likelihood of getting the influenza vaccine compared to non-Hispanic White patients.

A modeling study projected an annual reduction of nearly 25 000 infant hospitalizations and 46 000 ED encounters following maternal vaccination against RSV.

Immune response in older adults after receiving both vaccines in the same visit was noninferior to sequential administration and the safety profile was acceptable.

The study found that measles antibody levels during 2 long-term follow-ups fell lower than those observed before receipt of the third MMR dose.

The study findings on enhanced immunity from a third mRNA-1273 dose and specific population benefits will help build effective public health policy, authors say.

The intranasal delivery and live attenuated form of CoviLiv may strengthen immune response and vaccine acceptance and uptake in populations and regions where both are low.

Researchers say findings demonstrate the capacity to use an existing influenza vaccine effectiveness network to study a large immunocompromised population.

IDWeek 2023: In a large cohort of people living with HIV, those switching from oral ART to long acting CAB+RPV were more than 4x as likely to adhere to the regimen.

Approved for persons with HIV with undetectable VL, CAB+RPV LA may also be appropriate for those with VL ≥50 copies when the therapy is initiated, according to new findings.